NASDAQ: $VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and endocrine diseases, has officially announced the date for its upcoming financial report. Investors and interested parties can anticipate the company’s financial results for the fourth quarter and the full year ended December 31, 2025, which will be released after market close on Wednesday, February 11, 2026.
In conjunction with the release of these financial figures, Viking Therapeutics management will host a conference call and live webcast to discuss the results. This briefing is scheduled to take place on the same day, February 11, 2026, at 4:30 p.m. Eastern Time (ET).
The conference call will provide stakeholders with comprehensive details regarding the company’s financial performance throughout the final quarter and the entirety of the 2025 fiscal year. Furthermore, management is expected to offer commentary on operational milestones achieved during the period and provide strategic outlook updates concerning their clinical pipeline. Viking Therapeutics continues to advance several promising candidates, particularly in areas addressing significant unmet medical needs related to metabolic health.
For those wishing to listen to the live webcast, a link will be made available in the ‘Investors & Media’ section of the company’s official website, www.vikingtherapeutics.com. A replay of the webcast will also be accessible on the website for a limited time following the conclusion of the live event.
The upcoming earnings call represents a key opportunity for the market to evaluate the financial health and operational progress of Viking Therapeutics as it moves forward with its clinical development programs. Investors often look closely at these reports for updates on cash runway, research and development expenditures, and milestones related to pipeline progression, especially concerning lead candidates that may be approaching pivotal trial readouts.
This announcement follows the standard procedural cadence for publicly traded companies reporting quarterly and annual financial information to regulatory bodies and the investing public.